Kidney Res Clin Pract > Epub ahead of print |
Funding
This work was supported in part by a Cooperative Research Grant 2019 from the Korean Society of Nephrology, and this work was also supported by a grant from the Patient-Centered Clinical Research Coordinating Center (PACEN) funded by the Ministry of Health & Welfare, Republic of Korea (grant number: RS-2021-KH120073).
Acknowledgments
We would like to acknowledge Korean Society of Geriatric Nephrology consortium members and their affiliations for their support towards this study: Sungjin Chung and Yeouido St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea (president); Gang-Jee Ko, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea (vice-president); Young Youl Hyun, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea (Secretary General) (Available at http://gsn.or.kr/common_files/about_03.asp, April 12, 2024, this is the current list of executive committees from the KSGN official homepage). We would also like to thank Jinseob Kim (Zarathu Co., Ltd., Seoul, Republic of Korea) for their support in performing statistical analysis.
Characteristic | Total | 6-Month death | 6-Month alive | p-value |
---|---|---|---|---|
No. of patients | 1,751 | 271 | 1,480 | |
Age at the HD initiation (yr) | ||||
70–74 | 609 (34.8) | 57 (21.0) | 552 (37.3) | <0.001a |
75–79 | 583 (33.3) | 90 (33.2) | 493 (33.3) | |
80–84 | 359 (20.5) | 59 (21.8) | 300 (20.3) | |
≥85 | 200 (11.4) | 65 (24.0) | 135 (9.1) | |
Sex | ||||
Female | 772 (44.1) | 117 (43.2) | 655 (44.3) | 0.79a |
Male | 979 (55.9) | 154 (56.8) | 825 (55.7) | |
Body mass index (kg/m2) | ||||
<18.5 | 147 (8.4) | 43 (15.9) | 104 (7.0) | <0.001a |
18.5–22.9 | 745 (42.5) | 118 (43.5) | 627 (42.4) | |
23.0–24.9 | 370 (21.1) | 52 (19.2) | 318 (21.5) | |
25.0–29.9 | 392 (22.4) | 46 (17.0) | 346 (23.4) | |
≥30.0 | 97 (5.5) | 12 (4.4) | 85 (5.7) | |
Primary etiology | ||||
Glomerulonephritis | 856 (48.9) | 104 (38.4) | 752 (50.8) | 0.002a |
Diabetic kidney disease | 122 (7.0) | 19 (7.0) | 103 (7.0) | |
Hypertension | 439 (25.1) | 83 (30.6) | 356 (24.1) | |
Others | 334 (19.1) | 65 (24.0) | 269 (18.2) | |
Malignancy | ||||
Curative state | 235 (13.4) | 53 (19.6) | 182 (12.3) | <0.001a |
Ongoing or palliative treatment | 53 (3.0) | 18 (6.6) | 35 (2.4) | |
Malignancy with metastatic disease | 73 (4.2) | 27 (10.0) | 46 (3.1) | <0.001a |
Ischemic heart disease | 391 (22.3) | 63 (23.2) | 328 (22.2) | 0.75a |
Cerebrovascular disease | 326 (18.6) | 48 (17.7) | 278 (18.8) | 0.74a |
Congestive heart failure | 333 (19.0) | 70 (25.8) | 263 (17.8) | 0.002a |
Atrial fibrillation | 191 (10.9) | 43 (15.9) | 148 (10.0) | 0.006a |
Diabetes mellitus | 1,029 (58.8) | 134 (49.4) | 895 (60.5) | 0.001a |
Hypertension | 1,582 (90.3) | 226 (83.4) | 1,356 (91.6) | <0.001a |
Activities of daily living dependency | ||||
None | 1,053 (60.1) | 116 (42.8) | 937 (63.3) | <0.001a |
Partial | 485 (27.7) | 95 (35.1) | 390 (26.4) | |
Total | 213 (12.2) | 60 (22.1) | 153 (10.3) | |
Severe behavior disorder | 99 (5.7) | 25 (9.2) | 74 (5.0) | 0.009a |
Hospitalization history prior to HD initiation within 6 mo | ||||
None | 1,181 (67.4) | 172 (63.5) | 1,009 (68.2) | 0.02a |
<1 mo | 512 (29.2) | 83 (30.6) | 429 (29.0) | |
More than 1 mo | 58 (3.3) | 16 (5.9) | 42 (2.8) | |
Nursing hospital care at dialysis initiation | 167 (9.5) | 43 (15.9) | 124 (8.4) | <0.001a |
Vascular access at dialysis initiation | ||||
Temporary catheter | 1,425 (81.4) | 254 (93.7) | 1,171 (79.1) | <0.001a |
AVF | 256 (14.6) | 14 (5.2) | 242 (16.4) | |
AVG | 70 (4.0) | 3 (1.1) | 67 (4.5) | |
Vascular access on maintenance dialysis | ||||
Temporary catheter | 304 (17.4) | 137 (50.6) | 167 (11.3) | <0.001a |
AVF | 1,115 (63.7) | 101 (37.3) | 1,014 (68.5) | |
AVG | 332 (19.0) | 33 (12.2) | 299 (20.2) | |
Albumin (g/dL) | ||||
<3.5 | 939 (53.6) | 194 (71.6) | 745 (50.3) | <0.001a |
≥3.5 | 812 (46.4) | 77 (28.4) | 735 (49.7) | |
eGFR (mL/min/1.73 m2) | ||||
≤15 | 138 (7.9) | 40 (14.8) | 98 (6.6) | <0.001a |
>15 | 1,613 (92.1) | 231 (85.2) | 1,382 (93.4) | |
Total cholesterol (mg/dL) | ||||
<200 | 1,548 (88.4) | 244 (90.0) | 1,304 (88.1) | 0.42a |
≥200 | 203 (11.6) | 27 (10.0) | 176 (11.9) | |
Hemoglobin (g/dL) | 9.3 ± 3.0 | 9.1 ± 1.7 | 9.3 ± 2.4 | 0.25b |
Blood urea nitrogen (mg/dL) | 78.5 ± 34.5 | 76.2 ± 35.3 | 79.0 ± 34.4 | 0.23b |
Sodium (eEq/L) | 136.4 ± 7.5 | 135.7 ± 6.2 | 136.5 ± 7.7 | 0.05b |
Potassium (mEq/L) | 4.9 ± 3.8 | 4.7 ± 1.1 | 4.9 ± 4.1 | 0.047b |
Total CO2 (mEq/L) | 18.7 (15.1–22.0) | 18.1 (15.0–22.0) | 18.7 (15.3–22.0) | 0.67c |
Uric acid (mg/dL) | 7.8 ± 2.9 | 7.9 ± 3.3 | 7.8 ± 2.8 | 0.66b |
Calcium (mg/dL) | 8.2 ± 1.0 | 8.2 ± 0.9 | 8.2 ± 1.0 | 0.98b |
Phosphorus (mg/dL) | 4.8 (3.9–5.8) | 4.8 (3.6–5.8) | 4.8 (3.9–5.8) | 0.44c |
Magnesium (mg/dL) | 2.4 ± 0.6 | 2.4 ± 0.6 | 2.4 ± 0.6 | 0.44b |
AST (IU/L) | 19.0 (14.0–25.0) | 21.0 (15.0–32.0) | 18.0 (14.0–25.0) | <0.001c |
ALT (IU/L) | 13.0 (9.0–21.0) | 14.0 (9.0–23.0) | 13.0 (9.00–21.0) | 0.21c |
ALP (IU/L) | 107.0 (71.0–226.0) | 115.0 (73.5–246.0) | 105.0 (70.0–223.0) | 0.13c |
CPK (IU/L) | 102.0 (57.0–182.0) | 76.0 (44.0–158.0) | 106.5 (59.0–189.3) | 0.001c |
LDH (IU/L) | 333.0 (243.0–476.0) | 367.0 (248.0–500.0) | 327.0 (242.0–470.0) | 0.08c |
Data are expressed as number only, number (%), mean ± standard deviation, or median (interquartile range).
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AVF, arteriovenous fistula; AVG, arteriovenous graft; CPK, creatine phosphokinase; eGFR, estimated glomerular filtration rate; HD, hemodialysis; LDH, lactate dehydrogenase.
Variable | Univariate OR (95% CI) | p-valuea | Multivariate with stepwise selection OR (95% CI) | p-valueb | Final score (coefficient) |
---|---|---|---|---|---|
Age (yr) | |||||
70–74 | Reference | ||||
75–79 | 1.77 (1.24–2.52) | 0.002 | 1.39 (0.96–2.05) | 0.08 | |
80–84 | 1.90 (1.29–2.81) | 0.001 | 1.31 (0.86–2.00) | 0.22 | |
≥85 | 4.66 (3.12–6.97) | <0.001 | 3.06 (1.96–4.76) | <0.001 | 2 |
Sex | |||||
Female | Reference | ||||
Male | 1.05 (0.80–1.36) | 0.741 | |||
Body mass index (kg/m2) | |||||
25.0–29.9 | Reference | ||||
<18.5 | 3.11 (1.94–4.98) | <0.001 | |||
18.5–22.9 | 1.42 (0.98–2.04) | 0.06 | |||
23.0–24.9 | 1.23 (0.80–1.88) | 0.34 | |||
≥30.0 | 1.06 (0.54–2.09) | 0.86 | |||
Primary etiology | |||||
Glomerulonephritis | Reference | ||||
Diabetic kidney disease | 1.33 (0.78–2.27) | 0.29 | 0.88 (0.47–1.65) | 0.71 | |
Hypertension and renovascular disease | 1.69 (1.23–2.31) | 0.001 | 1.69 (1.19–2.39) | 0.003 | 1 |
Others | 1.75 (1.24–2.45) | 0.001 | 1.21 (0.82–1.78) | 0.34 | |
Malignancy | |||||
None | Reference | ||||
Curative state | 1.84 (1.31–2.58) | <0.001 | 1.57 (1.07–2.30) | 0.02 | 1 |
Ongoing or palliative treatment | 3.25 (1.80–5.85) | <0.001 | 2.06 (1.05–4.03) | 0.03 | 1 |
Malignancy with metastatic disease | |||||
No | Reference | ||||
Yes | 3.45 (2.10–5.65) | <0.001 | |||
Ischemic heart disease | |||||
No | Reference | ||||
Yes | 1.06 (0.78–1.45) | 0.69 | |||
Cerebrovascular disease | |||||
No | Reference | ||||
Yes | 0.93 (0.66–1.30) | 0.68 | |||
Congestive heart failure | |||||
No | Reference | ||||
Yes | 1.61 (1.19–2.18) | 0.002 | |||
Atrial fibrillation | |||||
No | Reference | ||||
Yes | 1.70 (1.18–2.45) | 0.005 | |||
Diabetes mellitus | |||||
No | Reference | ||||
Yes | 0.64 (0.49–0.83) | <0.001 | |||
Hypertension | |||||
No | Reference | ||||
Yes | 0.46 (0.32–0.66) | <0.001 | 0.59 (0.38–0.92) | 0.02 | –1 |
Activities of daily living dependency | |||||
None | Reference | ||||
Partial | 1.97 (1.46–2.64) | <0.001 | |||
Total | 3.17 (2.22–4.52) | <0.001 | |||
Severe behavior disorder | |||||
No | Reference | ||||
Yes | 1.93 (1.20–3.10) | 0.006 | |||
Hospitalization history prior to HD initiation within 6 mo | |||||
None | Reference | ||||
<1 mo | 1.13 (0.85–1.51) | 0.38 | |||
More than 1mo | 2.23 (1.23–4.06) | 0.008 | |||
Nursing hospital care at dialysis initiation | |||||
No | |||||
Yes | 2.06 (1.42–3.00) | <0.001 | |||
Vascular access at dialysis initiation | |||||
Temporary catheter | Reference | ||||
AVF | 0.27 (0.15–0.46) | <0.001 | |||
AVG | 0.21 (0.06–0.66) | 0.008 | |||
Vascular access on maintenance dialysis | |||||
Temporary catheter | Reference | ||||
AVF | 0.12 (0.09–0.16) | <0.001 | 0.16 (0.12–0.22) | <0.001 | –3 |
AVG | 0.13 (0.09–0.21) | <0.001 | 0.17 (0.11–0.27) | <0.001 | –3 |
Albumin (g/dL) | |||||
≥3.5 | Reference | ||||
<3.5 | 2.49 (1.87–3.30) | <0.001 | 1.85 (1.36–2.53) | <0.001 | 1 |
eGFR (mL/min/1.73 m2) | |||||
>15 | Reference | ||||
≤15 | 0.41 (0.28–0.61) | <0.001 | |||
Total cholesterol (mg/dL) | |||||
<200 | Reference | ||||
≥200 | 0.82 (0.53–1.26) | 0.36 |
Variable | Total (n = 404) | 6-Month death (n = 41) | 6-Month alive (n = 363) | p-value |
---|---|---|---|---|
Age at the hemodialysis initiation (yr) | 0.80a | |||
70–74 | 86 (21.3) | 11 (26.8) | 75 (20.7) | |
75–79 | 116 (28.7) | 11 (26.8) | 105 (28.9) | |
80–84 | 116 (28.7) | 10 (24.4) | 106 (29.2) | |
≥85 | 86 (21.3) | 9 (22.0) | 77 (21.2) | |
Sex | 0.41a | |||
Female | 187 (46.3) | 22 (53.7) | 165 (45.5) | |
Male | 217 (53.7) | 19 (46.3) | 198 (54.5) | |
Body mass index (kg/m2) | 0.67a | |||
<18.5 | 38 (9.4) | 6 (14.6) | 32 (8.8) | |
18.5–22.9 | 153 (37.9) | 13 (31.7) | 140 (38.6) | |
23.0–24.9 | 94 (23.3) | 11 (26.8) | 83 (22.9) | |
25.0–29.9 | 91 (22.5) | 9 (22.0) | 82 (22.6) | |
≥30.0 | 28 (6.9) | 2 (4.9) | 26 (7.2) | |
Primary etiology | 0.14a | |||
Glomerulonephritis | 186 (46.0) | 20 (48.8) | 166 (45.7) | |
Diabetic kidney disease | 37 (9.2) | 2 (4.9) | 35 (9.6) | |
Hypertension | 125 (30.9) | 9 (22.0) | 116 (32.0) | |
Others | 56 (13.9) | 10 (24.4) | 46 (12.7) | |
Malignancy | 0.37a | |||
No | 313 (77.5) | 29 (70.7) | 284 (78.2) | |
Yes | 91 (22.5) | 12 (29.3) | 79 (21.8) | |
Malignancy with metastatic disease | 18 (17.6) | 2 (13.3) | 16 (18.4) | >0.99a |
Ischemic heart disease | 73 (18.1) | 7 (17.1) | 66 (18.2) | >0.99a |
Cerebrovascular disease | 114 (28.2) | 11 (26.8) | 103 (28.4) | 0.98a |
Congestive heart failure | 83 (20.5) | 14 (34.1) | 69 (19.0) | 0.04a |
Atrial fibrillation | 31 (7.7) | 4 (9.8) | 27 (7.4) | 0.54a |
Diabetes mellitus | 235 (58.2) | 24 (58.5) | 211 (58.1) | >0.99a |
Hypertension | 344 (85.1) | 35 (85.4) | 309 (85.1) | >0.99a |
Severe behavior disorder | 34 (8.4) | 4 (9.8) | 30 (8.3) | 0.77a |
Hospitalization history prior to HD initiation within 6 mo | 0.11a | |||
None | 198 (49.0) | 22 (53.7) | 176 (48.5) | |
<1 mo | 159 (39.4) | 11 (26.8) | 148 (40.8) | |
More than 1 mo | 47 (11.6) | 8 (19.5) | 39 (10.7) | |
Nursing hospital care at dialysis initiation | 20 (5.0) | 2 (4.9) | 18 (5.0) | >0.99a |
Vascular access at dialysis initiation | 0.60a | |||
Temporary catheter | 349 (86.4) | 37 (90.2) | 312 (86.0) | |
AVF | 55 (13.6) | 4 (9.8) | 51 (14.0) | |
AVG | 0 (0) | 0 (0) | 0 (0) | |
Vascular access on maintenance dialysis | 0.37a | |||
Temporary catheter | 71 (17.6) | 8 (19.5) | 63 (17.4) | |
AVF | 313 (77.5) | 33 (80.5) | 280 (77.1) | |
AVG | 20 (5.0) | 0 (0) | 20 (5.5) | |
Albumin (g/dL) | 0.45a | |||
≥3.5 | 185 (45.8) | 16 (39.0) | 169 (46.6) | |
<3.5 | 219 (54.2) | 25 (61.0) | 194 (53.4) | |
eGFR (mL/min/1.73 m2) | 0.25a | |||
≤15 | 37 (9.2) | 6 (14.6) | 31 (8.5) | |
>15 | 367 (90.8) | 35 (85.4) | 332 (91.5) | |
Hemoglobin (g/dL) | 9.03 ± 1.76 | 8.96 ± 2.13 | 9.04 ± 1.72 | 0.83b |
Data are expressed as number (%) or mean ± standard deviation. In malignancy, no was defined as no history of cancer, and yes was defined as a curative state, ongoing or palliative treatment state.
AVF, arteriovenous fistula; AVG, arteriovenous graft; eGFR, estimated glomerular filtration rate; HD, hemodialysis.
Woo Yeong Park
https://orcid.org/0000-0003-2662-2898
Eunjin Bae
https://orcid.org/0000-0001-6890-4725
Hui-Seung Lee
https://orcid.org/0000-0002-7061-9680
Chi-Yeon Lim
https://orcid.org/0000-0003-0178-6976
Jang-Hee Cho
https://orcid.org/0000-0002-7031-5214
Byung Chul Yu
https://orcid.org/0000-0002-2686-1904
Miyeun Han
https://orcid.org/0000-0001-7304-2496
Sang Heon Song
https://orcid.org/0000-0002-8218-6974
Gang-Jee Ko
https://orcid.org/0000-0001-8355-1083
Jae Won Yang
https://orcid.org/0000-0003-3689-5865
Sungjin Chung
https://orcid.org/0000-0002-9886-8339
Yu Ah Hong
https://orcid.org/0000-0001-7856-4955
Young Youl Hyun
https://orcid.org/0000-0002-4204-9908
In O Sun
https://orcid.org/0000-0001-7245-3736
Hyunsuk Kim
https://orcid.org/0000-0003-1889-253X
Won Min Hwang
https://orcid.org/0000-0001-7548-6111
Sung Joon Shin
https://orcid.org/0000-0002-0777-9278
Soon Hyo Kwon
https://orcid.org/0000-0002-4114-4196
Kyung Don Yoo
https://orcid.org/0000-0001-6545-6517
Hydration Status in Elderly Hemodialysis Patients: Bioimpedance Analysis2011 November;30(6)